search
Back to results

A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers

Primary Purpose

Dry Eye Syndromes

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
5% GLH8NDE
Placebos
Sponsored by
GL Pharm Tech Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dry Eye Syndromes

Eligibility Criteria

20 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy subject who, at the time of screening, are the age between 20 and 50 years
  • Subject who has body weight between 55.0 and 90.0 kg, and BMI between 18.0 and 27.0
  • Subject who signed and dated the informed consent form after understanding fully to hear a detailed explanation in the clinical trial

Exclusion Criteria:

  • A subject who has a evidence or history of clinically significant hepatic, renal, neurologic, pulmonary, endocrine, urological, psychiatric, cardiovascular, hematological, oncological, etc.
  • A subject who has a history of disease with myocardial infarction, stroke, arrhythmia, hypotension (90 mmHg amine or diastolic blood pressure less than 50 mmHg at screening), uncontrolled hypertension (greater than 170 mmHg diastolic blood pressure or 100 mmHg diastolic blood pressure at screening), coronary artery, or who has a current abnormality
  • A subject with a history of hypersensitivity to the drug (aspirin, antibiotics, etc.) or clinical significant hypersensitivity reactions
  • A subject with the following findings in paperweight, visual acuity test, front eye photo, corneal refraction test, intraocular pressure test, slit lamp microscopy examination, fundus examination, tear break-up time examination, tear secretion test, OSDI (ocular surface disease index) are excluded

    1. A subject with suspected history or symptoms of visual organs, including keratitis, uveitis, retinitis, dry eye and strabismus
    2. A subject who has had eye surgery (including those who have received more than 6 months for eye laser surgery)
    3. A subject at least one eye with an intra-ocular pressure of 22 mmHg or more at the screening
    4. At the screening, tear break-up time of at least one eye in both eyes is less than 10 seconds and diagnosed as dry eye according to OSDI test
    5. A subject whose ratio for at least one eye in both eyes during screening is less than 10 mm as measured for 5 minutes in an Un-anesthetized Schirmer's test
    6. There are side effects to people who wear contact lenses after wearing them or within a month
  • A subject with a history of drug abuse or a positive urine drug screening for drug abuse
  • A subject who has participated in any other clinical trials and bioequivalence had medication within 6 months prior to the first administration of investigational product (The end date of another clinical trial is based on the last day of the administration)
  • A subject who has taken any ethical-the-counter drug or herbal drug within 2 weeks has taken any over-the-counter drug or vitamin include artificial tears within 1 week before the investigational product
  • A subject who has donated whole blood within 2 months or blood components within 1 month prior to the investigational product administration
  • History of regular alcohol consumption exceeding 21 units/week (1 unit = 10 g of pure alcohol) within 60 days before the investigational product or non-stop the alcohol drinking
  • The current smoker, but except the subject to quit the smoke over 90 days
  • Recognized contraceptive methods (e.g. your and your partner's infertility surgery, your partner's intrauterine device (IUD), cervical caps or contraceptive diaphragms for use with spermicides) Single block), cervical cap or contraceptive diaphragm with male condom (double block)]
  • A subject who have to work that cause excessive eye fatigue during this clinical trial
  • A subject who is not eligible for the study due to reasons on the investigators' judgement

Sites / Locations

  • Seoul National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

The A group in 5% GLH8NDE

The A group in placebo

The B group in 5% GLH8NDE

The B group in placebo

The C group in 5% GLH8NDE

The C group in placebo

The D group in 5% GLH8NDE

The D group in placebo

Arm Description

Three times administration both eyes, each 1 drop in Korean

Three times administration both eyes, each 1 drop in Korean

Six administration both eyes, each 1 drop in Korean

Six administration both eyes, each 1 drop in Korean

Six administration both eyes, each 2 drop in Korean

Six administration both eyes, each 2 drop in Korean

Six administration both eyes, each 2 drop in Caucasian

Six administration both eyes, each 2 drop in Caucasian

Outcomes

Primary Outcome Measures

Adverse events
To 18 days after first IP administration
Vital signs in blood pressure
Whether out of normal range at Blood pressure (SBP, DBP)
Vital signs in pulse
Whether out of normal range at Pulse rate
Vital signs in temperature
Whether out of normal range in temperature at eardrum
Physical examinations in weight change
Weight change in kilograms
Clinical laboratories in blood sample
Whether abnormal blood chemistry
Clinical laboratories in blood sample
Whether positive at Type B hepatitis, Type C hepatitis, HIV, and Syphilis
12-lead ECG in clinical significance
Whether out of normal range QRS complex
Ophthalmic symptom
To 18 days after first IP administration
Ophthalmic examination
Tear break-up time examination
AUClast in ng·h/mL
One day administration as GLH8NDE
AUCinf in ng·h/mL
One day administration as GLH8NDE
Cmax in ng/mL
One day administration as GLH8NDE
Tmax in ng/mL
One day administration as GLH8NDE
t1/2 in hour
One day administration as GLH8NDE
AUCtau,ss in ng·h/mL
Mutiple dose administration as GLH8NDE
Cmax in ng/mL
Mutiple dose administration as GLH8NDE
Tmax in ng/mL
Mutiple dose administration as GLH8NDE
t1/2 in hour
Mutiple dose administration as GLH8NDE
R(Accumulation index)
Accumulation in dex at mutiple dose administration as GLH8NDE

Secondary Outcome Measures

Full Information

First Posted
September 20, 2019
Last Updated
December 17, 2020
Sponsor
GL Pharm Tech Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT04104997
Brief Title
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
Official Title
A Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
September 26, 2019 (Actual)
Primary Completion Date
February 18, 2020 (Actual)
Study Completion Date
July 17, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GL Pharm Tech Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a randomized, double-blind, placebo-controlled phase 1 clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of GLH8NDE after single and multiple ocular administrations in healthy Korean and Caucasian volunteers

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye Syndromes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
39 (Actual)

8. Arms, Groups, and Interventions

Arm Title
The A group in 5% GLH8NDE
Arm Type
Experimental
Arm Description
Three times administration both eyes, each 1 drop in Korean
Arm Title
The A group in placebo
Arm Type
Placebo Comparator
Arm Description
Three times administration both eyes, each 1 drop in Korean
Arm Title
The B group in 5% GLH8NDE
Arm Type
Experimental
Arm Description
Six administration both eyes, each 1 drop in Korean
Arm Title
The B group in placebo
Arm Type
Placebo Comparator
Arm Description
Six administration both eyes, each 1 drop in Korean
Arm Title
The C group in 5% GLH8NDE
Arm Type
Experimental
Arm Description
Six administration both eyes, each 2 drop in Korean
Arm Title
The C group in placebo
Arm Type
Placebo Comparator
Arm Description
Six administration both eyes, each 2 drop in Korean
Arm Title
The D group in 5% GLH8NDE
Arm Type
Experimental
Arm Description
Six administration both eyes, each 2 drop in Caucasian
Arm Title
The D group in placebo
Arm Type
Placebo Comparator
Arm Description
Six administration both eyes, each 2 drop in Caucasian
Intervention Type
Drug
Intervention Name(s)
5% GLH8NDE
Intervention Description
5% GLH8NDE as eye drops
Intervention Type
Drug
Intervention Name(s)
Placebos
Intervention Description
Placebo as eye drops
Primary Outcome Measure Information:
Title
Adverse events
Description
To 18 days after first IP administration
Time Frame
Between 1 day before first IP administration and 18 days
Title
Vital signs in blood pressure
Description
Whether out of normal range at Blood pressure (SBP, DBP)
Time Frame
Each point at Screening(between 2 day and 28 day before IP administration), 1, 2, 4, 6, 8, 10, 11 days, and post-study visit(between 16 and 18 days)
Title
Vital signs in pulse
Description
Whether out of normal range at Pulse rate
Time Frame
Each point at Screening(between 2 day and 28 day before IP administration), 1, 2, 4, 6, 8, 10, 11 days, and post-study visit(between 16 and 18 days)
Title
Vital signs in temperature
Description
Whether out of normal range in temperature at eardrum
Time Frame
Each point at Screening(between 2 day and 28 day before IP administration), 1, 2, 4, 6, 8, 10, 11 days, and post-study visit(between 16 and 18 days)
Title
Physical examinations in weight change
Description
Weight change in kilograms
Time Frame
Change trend of the each point among screening(between 2 day and 28 day before IP administration), 1, 2, 4, 6, 8, 10, 11 days, and post-study visit(between 16 and 18 days)
Title
Clinical laboratories in blood sample
Description
Whether abnormal blood chemistry
Time Frame
Each point at day 1, 2, 4, 6, 8, 10, and 11
Title
Clinical laboratories in blood sample
Description
Whether positive at Type B hepatitis, Type C hepatitis, HIV, and Syphilis
Time Frame
Each point at day 1, 2, 4, 6, 8, 10, and 11
Title
12-lead ECG in clinical significance
Description
Whether out of normal range QRS complex
Time Frame
Each point at Screening(between 2 day and 28 day before IP administration), 1, 4, 11 days, and post-study visit(between 16 and 18 days)
Title
Ophthalmic symptom
Description
To 18 days after first IP administration
Time Frame
Each point at Day 1, 2, 4, 6, 8, 10, and 11
Title
Ophthalmic examination
Description
Tear break-up time examination
Time Frame
Each point at Screening(between 2 day and 28 day before IP administration), 2, 11 days, and post-study visit(between 16 and 18 days)
Title
AUClast in ng·h/mL
Description
One day administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
AUCinf in ng·h/mL
Description
One day administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
Cmax in ng/mL
Description
One day administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
Tmax in ng/mL
Description
One day administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
t1/2 in hour
Description
One day administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
AUCtau,ss in ng·h/mL
Description
Mutiple dose administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
Cmax in ng/mL
Description
Mutiple dose administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
Tmax in ng/mL
Description
Mutiple dose administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
t1/2 in hour
Description
Mutiple dose administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration
Title
R(Accumulation index)
Description
Accumulation in dex at mutiple dose administration as GLH8NDE
Time Frame
Pre-dose, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours after last administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy subject who, at the time of screening, are the age between 20 and 50 years Subject who has body weight between 55.0 and 90.0 kg, and BMI between 18.0 and 27.0 Subject who signed and dated the informed consent form after understanding fully to hear a detailed explanation in the clinical trial Exclusion Criteria: A subject who has a evidence or history of clinically significant hepatic, renal, neurologic, pulmonary, endocrine, urological, psychiatric, cardiovascular, hematological, oncological, etc. A subject who has a history of disease with myocardial infarction, stroke, arrhythmia, hypotension (90 mmHg amine or diastolic blood pressure less than 50 mmHg at screening), uncontrolled hypertension (greater than 170 mmHg diastolic blood pressure or 100 mmHg diastolic blood pressure at screening), coronary artery, or who has a current abnormality A subject with a history of hypersensitivity to the drug (aspirin, antibiotics, etc.) or clinical significant hypersensitivity reactions A subject with the following findings in paperweight, visual acuity test, front eye photo, corneal refraction test, intraocular pressure test, slit lamp microscopy examination, fundus examination, tear break-up time examination, tear secretion test, OSDI (ocular surface disease index) are excluded A subject with suspected history or symptoms of visual organs, including keratitis, uveitis, retinitis, dry eye and strabismus A subject who has had eye surgery (including those who have received more than 6 months for eye laser surgery) A subject at least one eye with an intra-ocular pressure of 22 mmHg or more at the screening At the screening, tear break-up time of at least one eye in both eyes is less than 10 seconds and diagnosed as dry eye according to OSDI test A subject whose ratio for at least one eye in both eyes during screening is less than 10 mm as measured for 5 minutes in an Un-anesthetized Schirmer's test There are side effects to people who wear contact lenses after wearing them or within a month A subject with a history of drug abuse or a positive urine drug screening for drug abuse A subject who has participated in any other clinical trials and bioequivalence had medication within 6 months prior to the first administration of investigational product (The end date of another clinical trial is based on the last day of the administration) A subject who has taken any ethical-the-counter drug or herbal drug within 2 weeks has taken any over-the-counter drug or vitamin include artificial tears within 1 week before the investigational product A subject who has donated whole blood within 2 months or blood components within 1 month prior to the investigational product administration History of regular alcohol consumption exceeding 21 units/week (1 unit = 10 g of pure alcohol) within 60 days before the investigational product or non-stop the alcohol drinking The current smoker, but except the subject to quit the smoke over 90 days Recognized contraceptive methods (e.g. your and your partner's infertility surgery, your partner's intrauterine device (IUD), cervical caps or contraceptive diaphragms for use with spermicides) Single block), cervical cap or contraceptive diaphragm with male condom (double block)] A subject who have to work that cause excessive eye fatigue during this clinical trial A subject who is not eligible for the study due to reasons on the investigators' judgement
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
MinChang Kwon, Ph. D
Organizational Affiliation
GL PharmTech Corp.
Official's Role
Study Director
Facility Information:
Facility Name
Seoul National University Hospital
City
Seoul
State/Province
Jongno-gu
ZIP/Postal Code
03080
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers

We'll reach out to this number within 24 hrs